[WSJ] Will Gilead’s Hepatitis C Drug Bust State Budgets?

Will the cost of new hepatitis C treatments bust state budgets?

A new analysis suggests many states may, in fact, be overwhelmed as they attempt to pay for the Solvaldi medication sold by Gilead Sciences  GILD -0.41%, which costs $84,000 for each patient, and several forthcoming treatments that may be priced at a similar level.

Read More

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.